J. Düll

Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib‐resistant non‐nodal leukemic mantle cell lymphoma

A. Rosenwald, H. Einsele, K. M. Kortüm, 2020, European journal of haematology.

Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper

A. Rosenwald, J. Sancho, H. Tilly, 2022, Hematological oncology.

The use of tafasitamab in diffuse large B-cell lymphoma

G. Salles, M. Topp, J. Düll, 2021, Therapeutic advances in hematology.

Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

G. Salles, E. González-Barca, P. Abrisqueta, 2021 .

Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression

H. Einsele, M. Konopleva, H. Kantarjian, 2018, American journal of hematology.

CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma

A. Rosenwald, M. Srivastava, Angela Riedel, 2022, Cell Death Discovery.

A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement

A. Rosenwald, H. Einsele, M. Chatterjee, 2016, Clinical Cancer Research.

Phase 1 dose-escalation study of BI 836909, an anti-BCMA bi-specific T-cell engager, in relapsed and/or refractory multiple myeloma (RRMM).

H. Einsele, P. Moreau, C. Langer, 2016 .